Topical delivery of low-cost protein drug candidates made in chloroplasts for biofilm disruption and uptake by oral epithelial cells  by Liu, Yuan et al.
lable at ScienceDirect
Biomaterials 105 (2016) 156e166Contents lists avaiBiomaterials
journal homepage: www.elsevier .com/locate/biomateria lsTopical delivery of low-cost protein drug candidates made in
chloroplasts for bioﬁlm disruption and uptake by oral epithelial cells
Yuan Liu a, 1, Aditya C. Kamesh b, 1, Yuhong Xiao b, Victor Sun a, Michael Hayes b,
Henry Daniell b, *, Hyun Koo a, **
a Department of Orthodontics, Divisions of Pediatric Dentistry and Community Oral Health, School of Dental Medicine, University of Pennsylvania,
Philadelphia, PA 19104-6030, USA
b Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104-6030, USAa r t i c l e i n f o
Article history:
Received 27 May 2016
Received in revised form
27 July 2016
Accepted 31 July 2016
Available online 2 August 2016
Keywords:
Antimicrobial peptide
Drug delivery
Plant biopharmaceuticals
Dental caries
Therapeutic enzymes* Corresponding author. School of Dental Medicine
240 South 40th St, Rm#547, Levy Building, Philadelph
** Corresponding author. Department of Orthodo
Dentistry and Community Oral Health, School of De
Pennsylvania, 240 South 40th St, Rm#417, Levy Build
6030 USA.
E-mail addresses: hdaniell@upenn.edu (H. Daniell)
1 Both authors made equal contributions.
http://dx.doi.org/10.1016/j.biomaterials.2016.07.042
0142-9612/© 2016 The Authors. Published by Elseviera b s t r a c t
Protein drugs (PD) are minimally utilized in dental medicine due to high cost and invasive surgical
delivery. There is limited clinical advancement in disrupting virulent oral bioﬁlms, despite their high
prevalence in causing dental caries. Poor efﬁcacy of antimicrobials following topical treatments or to
penetrate and disrupt formed bioﬁlms is a major challenge. We report an exciting low-cost approach
using plant-made antimicrobial peptides (PMAMPs) retrocyclin or protegrin with complex secondary
structures (cyclic/hairpin) for topical use to control bioﬁlms. The PMAMPs rapidly killed the pathogen
Streptococcus mutans and impaired bioﬁlm formation following a single topical application of tooth-
mimetic surface. Furthermore, we developed a synergistic approach using PMAMPs combined with
matrix-degrading enzymes to facilitate their access into bioﬁlms and kill the embedded bacteria. In
addition, we identiﬁed a novel role for PMAMPs in delivering drugs to periodontal and gingival cells, 13
e48 folds more efﬁciently than any other tested cell penetrating peptides. Therefore, PDs fused with
protegrin expressed in plant cells could potentially play a dual role in delivering therapeutic proteins to
gum tissues while killing pathogenic bacteria when delivered as topical oral formulations or in chewing
gums. Recent FDA approval of plant-produced PDs augurs well for clinical advancement of this novel
concept.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biopharmaceuticals produced in current systems are prohibi-
tively expensive for a large majority of the global population. The
cost of protein drugs ($140 billion in 2013) exceeds GDP of >75% of
countries around the globe [1], making them unaffordable. One
third of global population earns <$2 per day or the low socio-
economic/underprivileged in the US can't afford protein drugs.
Such high costs are associated with their production in prohibi-
tively expensive fermenters, puriﬁcation, cold transportation/, University of Pennsylvania,
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Ltd. This is an open access article ustorage, short shelf life and sterile delivery methods [2,3]. In order
to address these concerns, low cost PDs can be made in plant cells
for their topical [4] or oral delivery [2,3,5].
Many infectious diseases in humans are caused by bioﬁlms,
including those occurring in the mouth [6,7]. For example, dental
caries continues to be the single most prevalent bioﬁlm-associated
oral disease, afﬂicting mostly underprivileged children and adults
in the US and worldwide, resulting in expenditures of >$40 billion
annually [8e10]. Caries-causing (cariogenic) bioﬁlms develop
when bacteria interact with dietary sugars and accumulate on
tooth surface, forming organized clusters that are ﬁrmly adherent
and enmeshed in an extracellular matrix of polymeric substances
such as exopolysaccharides (EPS) [9]. Streptococcus mutans is one of
the major pathogens causing dental caries, although additional
organisms may be involved [6,8e10]. This bacterium expresses
multiple exoenzymes (glucosyltransferases) that make it a primary
EPS producer in oral cavity, while it is also highly acidogenic and
aciduric [9]. Current topical antimicrobial modalities for controllingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the ‘gold standard’ for oral antimicrobial therapy, but has adverse
side effects including tooth staining and calculus formation, and is
not recommended for daily therapeutic use [11]. As an alternative,
several antimicrobial peptides (AMPs) have emerged with potential
antibioﬁlm effects against caries-causing oral pathogens, including
S. mutans [12,13].
When compared with conventional antibiotics, AMPs provide
additional advantages for oral antimicrobial therapy. For example,
AMPs not only possess bactericidal activity but also have other
biological functions like immunomodulation by activating mast
cells and wound healing [14], while playing a critical role in
angiogenesis [15]. Furthermore, they are potently active against
bacteria (particularly Gram-positive), fungi and viruses and can be
tailored to target speciﬁc pathogens by fusion with their surface
antigens [14,16,17]. AMPs can kill and restrict microbial infection by
multiple mechanisms, including altered cell surface charge,
disruption of membrane integrity and pore formation while also
neutralizing lipopolysaccharides-induced endotoxin shock
[14,16e19]. Although development of resistance is less likely with
AMPs, previous studies have shown that resistance mechanisms
can be developed by pathogens, including up-regulation of pro-
teolytic activity, release of scavenging anionic compounds such as
EPS and glycosaminoglycan, as well as amidation and related sur-
face conjugations of membrane lipids and/or peptidoglycan [18,19].
However, AMP structure and bioactivity varies greatly.
Linear AMPs have poor stability or antimicrobial activity when
compared to AMPs with complex secondary structures. For
example, retrocyclin (RC101) and protegrin-1 (PG1) have high
antimicrobial activity or stability when cyclized [20] or form
hairpin structure [21] with formation of disulﬁde bonds. RC101 is
highly stable at pH 3, 4, 7 and temperature 25 Ce37 C as well as in
human vaginal ﬂuid for 48 h [22], while the antimicrobial activity
was maintained for up to six months [23]. Likewise, PG1 is highly
stable in salt or human ﬂuids [24,25] but potency is lost when
linearized. Furthermore, AMPs displaying cyclic or secondary
structures have increased penetrability through the microbial
membranes compared to linear peptides [26]. These intriguing
characteristics of antimicrobial peptides with complex secondary
structures may facilitate development of novel therapeutics.
However, the high cost of producing sufﬁcient amounts of anti-
microbial peptides is a major barrier for their clinical development
and commercialization. Therefore, we have produced several low
cost antimicrobial peptides (magainin, retrocyclin, protegrin) in
plant chloroplasts [14,16,17].
Clinical therapy of bioﬁlm-associated infections faces yet
another challenging problem. Antimicrobial drugs often fail to kill
the clusters of microbes that are protected by their extracellular
matrix in formed bioﬁlms [27e29]. Therefore, EPS-matrix degrad-
ing enzymes from fungi (like dextranase or mutanase) have been
explored to disrupt bioﬁlm and prevent dental caries [30e33] but
with limited success [34,35]. However, a synergistic approach of
combining antimicrobial agents with EPS-matrix degrading en-
zymes has not yet been developed. In order to address the cost of
enzymes, we have developed a low cost strategy by producing
them in plant chloroplasts [36,37]. Most importantly, plant cells
expressing high levels of therapeutic proteins can be lyophilized
and stored at room temperature for several years [2,3,38,39].
Apart from treating oral bioﬁlm, protein therapy is minimally
utilized in dental medicine because of invasive surgical delivery.
However, there is a great need for delivery of growth hormones or
other bioactives to enhance cell adhesion, stimulate osteogenesis,
bone regeneration, differentiation of osteoblasts or endothelial
cells. In addition to minimal patient compliance, injectable protein
drugs often do not contain essential information to reach theirtarget cells or cell penetrating capabilities. Therefore, localized
targeting and delivery to cells including osteoblasts, periodontal
ligament cells, gingival epithelial cells or ﬁbroblasts is essential to
advance oral health. When delivered orally, protein drugs synthe-
sized in plant cells can be released by mechanical grinding
(chewing). Therefore, in this study, we investigate the speciﬁcity or
capability of cyclic or acyclic plant-made AMPs (PMAMPs) fused
with green ﬂuorescent protein to target various human periodontal
or gingival cells and evaluate their efﬁcacy in protein drug delivery.
In parallel, we evaluated the potency of PMAMPs to prevent bioﬁlm
formation following a topical treatment and their synergistic ac-
tivities with matrix degrading enzymes for disruption of formed
bioﬁlms. Thus, this study reports a new cost-effective approach for
production of protein drugs to prevent or treat bioﬁlm-associated
oral diseases and deliver PDs to human oral tissues for enhancing
oral health.
2. Materials and methods
2.1. Microorganisms and EPS degrading enzymes
Streptococcus mutans UA159 serotype c (ATCC 700610), Strep-
tococcus gordonii DL1 and Actinomyces naeslundii ATCC 12104 were
used in present study. The strains tested in this research were
selected because S. mutans is a well-established virulent cariogenic
bacteria [40]. S. gordonii is an early colonizer and considered an
accessory pathogen (that could enhance virulence of perio-
dontopathogens) [41]. A. naeslundii is also detected during the early
stages of bioﬁlm formation and may be associated with develop-
ment of dental root caries [42]. All these strains were grown in
ultra-ﬁltered (10 kDa molecular-weight cut-off membrane; Prep/
Scale, Millipore, MA) buffered tryptone-yeast extract broth (UFTYE;
2.5% tryptone and 1.5% yeast extract, pH 7.0) with 1% glucose to
mid-exponential phase (37 C, 5% CO2) prior to use. The EPS-
degrading enzymes dextranase and mutanase are capable of hy-
drolyzing a-1,6 and a-1,3 glucosidic linkages present in the EPS
glucans derived from S. mutans [43]. Dextranase produced from
Penicillium sp. was commercially purchased from Sigma (St. Louis,
MO) and mutanase produced from Trichoderma harzianum was
kindly provided by Dr. William H. Bowen (Center for Oral Biology,
University of Rochester Medical Center).
2.2. Puriﬁcation of tag-fused GFP proteins
The transplastomic plants expressing green ﬂuorescence pro-
tein (GFP) fused with Cholera Toxin B subunit (CTB), Protein
Transduction Domain (PTD), retrocyclin and protegrinwere created
as described in previous studies [16,38,44,45]. Puriﬁcation of GFP-
fused PG1 or RC101 from transplastomic tobacco was done from
0.2 to 1 gm of lyophilized plant material. Subsequent downstream
processing was done based on protocols established previously
[14,16,44] (also see Supplementary Fig. S1). The lyophilized mate-
rial was reconstituted in 10e20 ml of plant extraction buffer (0.2 M
Tris HCl pH 8.0, 0.1 M NaCl, 0.01 M EDTA, 0.4 M sucrose, 0.2% Triton
X supplemented with 2% phenylmethylsulfonylﬂuoride (PMSF) and
a protease inhibitor cocktail (Pierce). The resuspension was incu-
bated in ice for 1 h with vortex homogenization every 15 min. The
homogenates were then sonicated (Misonix sonicator 3000) and
spun down at 75,000 g at 4 C for 1 h (Beckman LE-80K optima
ultracentrifuge) to obtain the clariﬁed lysate. The lysate was sub-
jected to pretreatment with 70% saturated ammonium sulfate and
1/4th volume of 100% ethanol, followed by vigorous shaking for
2 min. The treated solutionwas spun down at 2100 g for 3 min. The
upper ethanol phase was collected and the process was repeated
with 1/16th volume of 100% ethanol. The pooled ethanol phases
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volume of 1-butanol, homogenized vigorously for 2 min and spun
down at 2100 g for 3 min. The lowermost phase was collected and
loaded onto a 7 kDa MWCO zeba spin desalting column (Thermo
scientiﬁc). The desalted extract was injected into a Toyopearl butyl
e 650S hydrophobic interaction column (Tosoh bioscience) which
was run on a FPLC unit (Pharmacia LKB-FPLC system). The column
was equilibrated with 2.3 column volumes of salted buffer (10 mM
Tris-HCl, 10 mM EDTA and 50% saturated ammonium sulfate) and
unsalted buffer (10 mM Tris-HCl, 10 mM EDTA) to a ﬁnal 20% salt
saturation to facilitate binding of GFP fusions onto the resin. This
was followed by a columnwash with 5.8 column volumes of salted
and unsalted buffer mix and then eluted with unsalted buffer. The
GFP fraction was identiﬁed and collected based on the peaks
observed in the chromatogram and dialyzed three times in 4 C.
The puriﬁed proteins were ﬁnally lyophilized (Labconco freezone
2.5) and then resuspended in sterile 1X PBS for all experiments.
2.3. Quantiﬁcation of puriﬁed GFP fusions
Puriﬁed GFP-fused RC101 or PG1 were quantiﬁed by running on
a 12% SDS gel followed by western blot (denatured conditions) or
native GFP ﬂuorescence. The western blots were probed using
mouse Anti-GFP antibody (Millipore) at 1:3000 dilution followed
by secondary probing with 1:4000 dilution of HRP conjugated
Goat-Anti Mouse antibody (Southern biotech). GFP ﬂuorescence
data was obtained by preparing and running GFP-fusion samples
under non-denaturing conditions. The native gels were ﬂuoresced
under UV light (Ultraviolet products Inc) and photographed.
Commercial GFP standards (Vector labs) were used to quantify GFP
fusions by both methods through densitometry using ImageJ soft-
ware to determine GFP concentration, expression level and yield.
Expression level was calculated fromGFP concentrations relative to
total protein values in plant crude extracts. Yield was determined
by multiplying GFP concentration with recovered volume after
puriﬁcation. Individual peptide yield was determined by dividing
GFP yield with molar factor 14 (ratio of GFP MW to peptide MW).
Total protein was determined by Bradford method.
2.4. Evaluation of antibacterial activity of plant-made antimicrobial
peptides (PMAMPs)
The antibacterial activity and killing kinetics of PMAMPs (GFP-
PG1 and GFP-RC101) against S. mutans were analyzed by the
determination of minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC) as well as time-lapse
killing assays as described previously [46]. S. mutans were grown
to log phase (105 CFU/ml), and GFP-PG1 or GFP-RC101 were added
to the growth medium at concentrations ranging from 1.25 to
160 mg/ml (two-fold dilution), respectively. At 0, 1, 2, 4, 8 and 24 h,
aliquots of bacterial suspensions were serially diluted and plated on
agar plates using an automated Eddy Jet spiral plater, and the col-
ony forming units (CFU) colonies were counted. Absorbance at
600 nm was also checked at each time point to measure growth
rate. Antibacterial activity against S. gordonii and A. naeslundii was
also determined to compare killing efﬁcacy (vs. S. mutans). Time-
lapsed confocal ﬂuorescence imaging was also performed to
assess the dynamics of S. mutans killing at single cell level. GFP-PG1
was added to actively growing (log-phase) S. mutans (105 CFU/ml)
at concentrations of 10 mg/ml in the presence of 2.5 mM propidium
iodide-PI (Molecular Probe Inc., Eugene, OR, USA) for labeling dead
cells. Confocal images were acquired in the same ﬁeld of view at 0,
10, 30, and 60 min using Leica SP5-FLIM inverted single photon
laser scanning microscope with a 100X (numerical aperture, 1.4) oil
immersion objective. The excitation wavelengths were 488 nm and543 nm for GFP and PI, respectively. The emission ﬁlter for GFP was
a 495/540 OlyMPFC1 ﬁlter, while PI was a 598/628 OlyMPFC2 ﬁlter.
Images were analyzed by ImageJ 1.44 [47].
In parallel, morphological observations of S. mutans treatedwith
PMAMPs (as described above) were also examined by scanning
electron microcopy. Actively growing S. mutans cells were prepared
as described above, andmixedwith GFP-PG1 (ﬁnal concentration of
10 mg/ml) for up to 1 h at 37 C. After treatment, the bacterial cells
were collected by ﬁltration (0.4 mmMillipore ﬁlter), and then ﬁxed
in 2.5% glutaraldehyde and 2.0% paraformaldehyde in 0.1 M caco-
dylate buffer (pH 7.4) for 1 h at room temperature and processed for
SEM (Quanta FEG 250, FEI, Hillsboro, OR) observation. Bacteria
treated with buffer only served as control.
2.5. Evaluation of anti-bioﬁlm activity of GFP-PG1
S. mutans bioﬁlms were formed on saliva-coated hydroxyapatite
(sHA) disc surfaces as detailed previously [47,48]. Hydroxyapatite
discs (1.25 cm in diameter, surface area of 2.7 ± 0.2 cm2, Clarkson,
Chromatography Products, Inc., South Williamsport, PA) were
coated with ﬁlter-sterilized, clariﬁed human whole saliva [47].
S. mutans was grown in UFTYE medium with 1% (w/v) glucose to
mid-exponential phase (37 C, 5% CO2). Before inoculum, sHA discs
were topically treated with GFP-PG1 solution (10 mg/ml) or buffer
only (vehicle-control) for 30 min. Chlorhexidine was used as pos-
itive control at the same concentration. Then, each of the treated
sHA discs were inoculated with 105 CFU of actively growing
S. mutans cells per ml in UFTYE medium containing 1% (w/v) su-
crose, and inoculated at 37 C and 5% CO2 for 19 h. EPS was labeled
using 2.5 mM Alexa Fluor 647-labeled dextran conjugate (10 kDa;
647/668 nm; Molecular Probes Inc.), while the bacteria cells were
stained with 2.5 mM SYTO9 (485/498 nm; Molecular Probes Inc.).
The imaging was performed using multi-photon Leica SP5 confocal
microscope with 20X (numerical aperture, 1.00) water immersion
objective. The excitationwavelength was 780 nm, and the emission
wavelength ﬁlter for SYTO 9 was a 495/540 OlyMPFEC1 ﬁlter, while
the ﬁlter for Alexa Fluor 647 was a HQ655/40M-2P ﬁlter. The
confocal image series were generated by optical sectioning at each
selected positions and step size of z-series scanning was 2 mm [47].
Amira 5.4.1 software (Visage Imaging, San Diego, CA, USA) was used
to create 3D renderings of bioﬁlm architecture [47,48].
We also examined the effects of PG1, alone or in combination
with EPS-degrading enzymes, on pre-formed bioﬁlms. Brieﬂy,
S. mutans bioﬁlms were allowed to accumulate on untreated sHA
discs for 19 h. Then, the bioﬁlms were treated with: 1) vehicle-
control, 2) EPS-degrading enzymes only, 3) PG1 only, or 4)
PG1þ EPS-degrading enzymes for up to 60 min. A mixture of 100 U
dextranase with 20 U mutanase (ratio of 5:1) was used based on
optimal enzyme amounts to degrade the EPS-matrixwithout killing
the cells or disturbing the integrity of the bioﬁlm 3D architecture as
determined experimentally in this study (Supplementary Fig. S2)
and in our previous publication [43]. Alexa Fluor 647-labeled
dextran conjugate was used to label the EPS-matrix, while SYTO 9
and PI were used to stain live cells and dead cells [47]. Fluorescence
images were taken at 0, 10, 30 and 60 min. The bioﬁlm 3D archi-
tecture was rendered using AMIRA, and total biomass of EPS, live
anddead cellswere quantiﬁed using COMSTATand ImageJ. The ratio
of live to the total bacteria at each time pointwas calculated, and the
survival rate of live cells (relative to live cells at 0min)was plotted as
described previously [47]. The initial number of viable cells at time
point 0 min was considered to be 100%. The percent-survival rate
was determined by comparing to time point 0 min [47]. Chlorhex-
idine at the same concentration was used as a positive control.
To complement the confocal imaging analysis, we also quanti-
ﬁed the number of viable cells in each of the bioﬁlms via standard
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titative PCR (PMA-qPCR) method. At selected time point (19 h),
bioﬁlms were removed, homogenized via sonication and subject to
microbiological analyses as detailed previously [47e49]; our soni-
cation procedure does not kill bacteria cells while providing opti-
mum dispersal and maximum recoverable counts. Aliquots of
bioﬁlm suspensions were serially diluted and plated on blood agar
plates using an antomated Eddy Jet Spiral Plater (IUL, SA, Barcelona,
Spain). The combination of PMA and qPCR will quantify only cells
with intact membrane (i.e. viable cells) because PMA cross-link the
DNA of dead cells and extracellular DNA, thereby preventing PCR
ampliﬁcation of DNA from these sources [49]. Brieﬂy, bioﬁlm pellets
were resuspended with 500 ml TE (50 mM Tris, 10 mM EDTA, pH
8.0). Using a pipette, the bioﬁlm suspensions were transferred to
1.5 ml microcentrifuge tubes; then mixed with PMA. 1.5 ml PMA
(20 mM in 20% dimethyl sulfoxide; Biotium, Hayward, CA) was
added to the bioﬁlm suspensions. The tubes were incubated in the
dark for 5 min, at room temperature, with occasional mixing. Next,
the samples were exposed to light for 3 min (600-W halogen light
source). After photo-induced cross-linking, the bioﬁlm suspensions
were centrifuged (13,000 g/10 min/4 C) and the supernatant was
discarded. The pellet was resuspended with 100 ml TE, following by
incubation with 10.9 ml lysozyme (100 mg/ml stock) and 5 ml
mutanolysin (5 U/ml stock) (37C/30 min). Genomic DNA was then
isolated using the MasterPure DNA puriﬁcation kit (Epicenter
Technologies, Madison, WI). Ten picograms of genomic DNA per
sample and negative controls (without DNA) were ampliﬁed by
MyiQ real-time PCR detection systemwith iQ SYBR Green supermix
(Bio-Rad Laboratories Inc., CA) and S. mutans speciﬁc primer (16S
rRNA) as detailed by Klein et al. [49].
2.6. Uptake of puriﬁed tag-fused GFP proteins and PMAMPs by
human oral cell lines
As previously described [44] uptake of GFP fused with CTB, PTD,
PG1 and RC101 was studied in human periodontal ligament stem
cells (HPDLS), maxilla mesenchymal stem cells (MMS), human head
and neck squamous cell carcinoma cells (SCC-1), gingiva-derived
mesenchymal stromal cells (GMSC), adult gingival keratinocytes
(AGK) and mouse osteoblast cells (OBC). Brieﬂy, 2  104 of each cell
line were incubated with puriﬁed GFP fusion tags in 100 ml PBS/1%
FBS at 37 C for 1 h. After ﬁxing with 2% paraformaldehyde and
stained with DAPI (Vector laboratories, Inc), all cells were imaged
using confocal microscopy. The images were observed under 100
objective, and at least 10e15 GFP-positive cells or images were
recorded for each cell line in three independent analysis. Further-
more, the level of ﬂuorescence intensity was determined using
ImageJ and at least ﬁve area of GFP positive cells were selected to
measure themean GFP density value. The normalized GFP intensity
was calculated by dividing the values (mean ﬂuorescence density
readings) from GFP fusion proteins by the values from GFP only. To
determine the relative GFP fusion tags uptake efﬁciency by gingiva-
derived mesenchymal stromal cells (GMSC) and adult gingival
keratinocytes (AGK), GMSC and AGK were cultured in chamber
slides at 37 C overnight, followed by incubation with puriﬁed GFP
fusion proteins at 37 C for 1 h. The level of ﬂuorescence intensity
was determined using ImageJ and at least ﬁve area of GFP positive
cells were selected to measure the mean GFP density value. The
normalized GFP intensity was calculated by dividing the values
(mean ﬂuorescence density readings) from GFP fusion proteins by
the values from GFP only.
2.7. Statistical analysis
Data are presented as the mean ± standard deviation (SD). Allthe assays were performed in duplicate in at least two distinct
experiments. Pair-wise comparisons were made between test and
control using Student's t-test. The chosen level of signiﬁcance for all
statistical tests in present study was P < 0.05.
3. Results
3.1. Expression and puriﬁcation of GFP fused antimicrobial peptides
from transplastomic plants
Leaves expressing GFP fused antimicrobial peptides RC101 and
PG1 (PMAMPs) were harvested from greenhouse and subsequently
lyophilized for long-term storage, protein extraction and puriﬁca-
tion. Expression levels of AMPs were similar to what was reported
previously [14,16]. Puriﬁcation of GFP fused to different antimi-
crobial peptides (RC101 and PG1) was done in order to test their
microbicidal activity against both planktonic and bioﬁlm forming
S. mutans. Lyophilized leaves expressing different GFP fusions were
used for extractions and subsequent downstream processing
(Supplementary Fig. S1) to obtain enriched or puriﬁed proteins.
Quantitation of puriﬁed GFP-RC101 and GFP-PG1 by both western
blot and native GFP ﬂuorescence gel methods showed high yield of
GFP-RC101 (1624 mg of GFP, 116 mg of RC101) per gm of lyophilized
leaf (Fig. 1A and B). In GFP-PG1 both methods showed lower levels
of yield (Fig. 1C and D), probably due to unique secondary struc-
tures in addition to lower level of expression. Thewestern blots also
showed GFP standards at 27 kDa which corresponds to the
monomer along with a 54 kDa GFP dimer. In GFP-RC101 western
blots, 29 kDa and 58 kDa polypeptides are clearly visible which
correspond to themonomer and dimer forms of the fusion (Fig. 1A).
This could be attributed to the ability of GFP to form dimers [50].
Native ﬂuorescence of GFP-RC101 and GFP-PG1 (Fig. 1B and D) and
western blots showed multimeric bands with some of them visible
below the 27 kDa GFP standard size which could be because of GFP
fusion to cationic peptides causing an electrophoretic mobility shift
as described in previous studies [16].
3.2. Antibacterial activity of PMAMPs
We ﬁrst examined the antimicrobial activity of PMAMPs using
dose-response studies. The MIC and MBC values of GFP-PG1 for
S. mutans were 1.25e2.5 mg/ml and 5e10 mg/ml, while for GFP-
RC101 the MIC and MBC were 10e20 mg/ml and 80e160 mg/ml.
Furthermore, GFP-PG1 displays potent antibacterial activity
(similar to synthetic PG1) against S. mutans, a proven bioﬁlm-
forming and caries-causing pathogen, rapidly killing the bacterial
cells within 1 h at low concentrations (Fig. 2A and B). GFP-RC101
was less efﬁcient in killing S. mutans than GFP-PG1 at similar
concentrations, probably due to impact of GFP fusion on cyclization
of retrocyclin (Fig. 2C and D). GFP-PG1 also killed other oral bacteria
including S. gordonii (that could enhance virulence of periodontal
pathogens) and A. naeslundii (associated with dental root caries)
(Fig. 2E). Time-lapse confocal imaging shows that S. mutans
viability is affected as early as 10 min as shown in Fig. 3A. SEM
imaging revealed disruption of S. mutans membrane surface,
causing irregular cell morphology as well as extrusion of the
intracellular content, while untreated bacteria showed intact and
smooth surfaces without any visible cell lysis or debris (Fig. 3B).
Having shown potent antimicrobial activity of GFP-PG1 against
S. mutans, we examined the potential of this PMAMP to prevent
bioﬁlm formation or disrupt pre-formed bioﬁlms.
3.3. Inhibition of bioﬁlm initiation by PMAMP PG1
Preventing the formation of pathogenic oral bioﬁlms is
Fig. 1. Puriﬁcation of GFP-fused Retrocyclin (RC101) and Protegrin (PG1) expressed in tobacco chloroplasts. (A) Western blot analysis of puriﬁed GFP-RC101 fusion using Anti-
GFP antibody. (B) Native ﬂuorescence gel of puriﬁed GFP-RC101 fusion. (C) Western blots of puriﬁed GFP-PG1 fusion using Anti-GFP antibody. (D) Native ﬂuorescence gel of puriﬁed
GFP-PG1.
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following topical applications. To determine whether GFP-PG1 can
disrupt the initiation of bioﬁlm, we treated saliva coated apatitic
(sHA) surface (tooth surrogate) with a single topical treatment of
GFP-PG1 for 30 min, and then incubated with actively growing
S. mutans cells in cariogenic (sucrose-rich) conditions. We observed
substantial impairment of bioﬁlm formation by S. mutans with
minimal accumulation of EPS-matrix on the GFP-PG1 treated sHA
surface (Fig. 4). The few adherent cell clusters were mostly non-
viable compared to control (Supplementary Fig. S3), demon-
strating potent effects of GFP-PG1 on bioﬁlm initiation despite
topical, short-term exposure. In addition, the inhibition of bioﬁlm
formation by PG1 was comparable to equivalent concentration of
chlorhexidine (CHX).3.4. Disruption of pre-formed bioﬁlm by PMAMP with or without
EPS-degrading enzymes
Cariogenic bioﬁlms already formed on tooth surfaces are noto-
riously difﬁcult to treat because drugs often fail to reach clusters of
pathogenic bacteria (such as S. mutans) that are surrounded and
enmeshed by an exopolysaccharides (EPS)-rich matrix, protecting
them against antimicrobials [9]. EPS-degrading enzymes such as
dextranase andmutanase could help digest thematrix of cariogenic
bioﬁlms. We ﬁrst optimized the units of dextranase and/or muta-
nase required for EPS-matrix disruption (Supplementary Fig. S2),
which were devoid of antibacterial effects. As shown in Fig. 5A, the
combination of dextranase and mutanase can digest the EPS (in
red) and ‘open space’ (see arrows) between the bacterial cell
clusters (in green) and ‘uncover’ cells (see arrows). Thus, thecombination of PG1 and EPS-degrading enzymes could potentiate
the overall antibioﬁlm effects.
To explore this concept, S. mutans bioﬁlms were pre-formed on
sHA surface, and treated topically with PG1 and EPS-degrading
enzymes (Dex/Mut) either alone or in combination. Time-lapsed
confocal imaging and quantitative computational analyses were
conducted to analyze EPS-matrix degradation and live/dead bac-
terial cells within bioﬁlms (Fig. 5B and C). The enzymes-peptide
combination resulted in more than 60% degradation of the EPS-
matrix, while increasing the bacterial killing when compared to
either PG1 or Dex/Mut alone. These ﬁndings were further validated
via standard culturing assays by determining colony forming units.
The antibacterial activity of PG1 against S. mutans bioﬁlms com-
bined with Dex/Mut was signiﬁcantly enhanced than either one
alone (Fig. 5D). Topical exposure of Dex/Mut alone showed no ef-
fects on bioﬁlm cell viability, whereas PG1 alone showed some
killing activity (Fig. 5C and D). Together, the data demonstrate
potential of this combined approach to signiﬁcantly enhance anti-
microbial efﬁcacy of PG1 against established bioﬁlms. Furthermore,
this approach was as effective as chlorhexidine combinedwith EPS-
degrading enzymes (Fig. 5D).3.5. Uptake of GFP fused proteins and PMAMPs by human
periodontal and gingival cells
Puriﬁed GFP fusion proteins or PMAMPs when incubated with
human cultured cells, including human periodontal ligament stem
cells (HPDLS), maxilla mesenchymal stem cells (MMS), head and
neck squamous cell carcinoma cells (SCC), gingiva-derived
mesenchymal stromal cells (GMSC), adult gingival keratinocytes
Fig. 2. Antimicrobial activity of PMAMPs (GFP-PG1 and GFP-RC101) against Streptococcus mutans and other oral bacteria. Cell viability was determined by absorbance (A600nm)
and counting colony forming units (CFU) over-time. (A) Time-killing curve of S. mutans treated with different concentrations of GFP-PG1 and synthetic PG1 (A600 nm). (B) Viable cells
(CFU/ml) of S. mutans treated with GFP-PG1 and synthetic PG1 at each time point. (C) Time-killing curve of S. mutans treated with GFP-RC101 at different concentrations (A600nm).
(D) Viable cells (CFU/ml) of S. mutans treated with GFP-RC101 at each time point. (E) Viable cells (CFU/ml) of S. gordonii and A. naeslundii treated with GFP-PG1 at 10 mg/ml for 1 h
and 2 h.
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results. Although only one representative image of each cell line is
presented, uptake studies were performed in triplicate and at least
10e15 images were recorded under confocal microscopy
(Fig. 6AeF). Without a fusion tag, GFP did not enter any tested
human cell line. Both CTB-GFP and PTD-GFP effectively penetrated
all tested cell types, although their localization patterns differed.
Upon incubation with CTB-GFP, GFP signals localized primarily to
the periphery of HPDLSC andMMSC, with small cytoplasmic puncta
in SSC-1, AGK, OBC and large cytoplasmic foci in GMSC. PTD-GFP
was observed as small cytoplasmic foci in MMSC, variably sized
cytoplasmic puncta in HPDLSC, GMSC, AGK, OBC and both the
cytoplasm and the periphery of SCC-1 cells. GFP-PG1 is the most
efﬁcient tag in penetrating all tested human cells because GFP
uptake in GMSC is 30-fold higher than CTB, 17-fold higher than PTD
and 48-fold higher than RC101. Likewise, in AGK cells GFP-PG1 GFP
accumulation is 28-fold higher than CTB, 13-fold higher than PTD
and 40-fold higher than RC101 (Fig. 6GeH). GFP-PG1 showed
exclusively cytoplasmic localization in HPDLSC, SCC-1, GMSC and
AGK cells and was localized in both the periphery and cytosol in
MMSC, but it is only localized in the periphery of OBC. GFP-RC101
entered SCC-1, GMSC, AGK and OBC, but its localization inHPDLSC was negligible and was undetectable in MMSC cells.4. Discussion
Development of new therapies against bioﬁlm-related oral
diseases and maintenance of oral health has been limited by
enormous economical and drug efﬁcacy hurdles. Therapeutic
agents need to be effective following topical applications to either
prevent bioﬁlm formation or disrupt formed bioﬁlms. Furthermore,
it needs to be affordable and readily accessible for majority of the
population affected by oral diseases, especially in lower socio-
economic communities [7,8]. Here, we report a novel therapeutic
concept for controlling oral bioﬁlms formed by a model cariogenic
pathogen and drug delivery to oral cells using chloroplast tech-
nology for low-cost production of plant-made antimicrobial pep-
tides (PMAMPs).
In cariogenic bioﬁlms, S. mutans can rapidly accumulate on tooth
surface through EPS production, and help to acidify the local
microenvironment promoting the growth of an acidogenic micro-
biota that eventually leads to the onset of dental caries [6,10,28,51].
Although other acidogenic bacteria contribute to caries pathogen-
esis, S. mutans is a key mediator by assembling an insoluble and
Fig. 3. Bacterial killing by GFP-PG1 as determined via confocal ﬂuorescence (A) and SEM imaging (B). (A) Time-lapse killing of S. mutans treated with GFP-PG1 at 10 mg/ml. The
control group consisted of S. mutans cells treated with buffer only. Propidium iodide (PI) (in red) was used with confocal microscopy to determine the bacterial viability over time at
single-cell level. PI is cell-impermeant and only enters cells with damaged membranes; in dying and dead cells a bright red ﬂuorescence is generated upon binding of PI to DNA.
GFP-PG1 is shown in green. (B) Morphological observations of S. mutans subjected to GFP-PG1 at a concentration of 10 mg/ml for 1 h using scanning electron microscopy. Red arrows
show dimpled membrane and extrusion of intracellular content.
Fig. 4. Inhibition of bioﬁlm formation by a single topical treatment of GFP-PG1. This ﬁgure displays representative images of three-dimensional (3D) rendering of S. mutans
bioﬁlm. Bacterial cells were stained with SYTO 9 (in green) and EPS were labeled with Alexa Fluor 647 (in red). Saliva-coated hydroxyapatite (sHA) disc surface was treated with a
single topical treatment of GFP-PG1 or chlorhexidine with a short-term 30 min exposure. The control group was treated with buffer only. Then, the treated sHA disc was transferred
to culture medium containing 1% (w/v) sucrose and actively growing S. mutans cells (105 CFU/ml) and incubated at 37 C, 5% CO2 for 19 h. After bioﬁlm growth, the bioﬁlms were
analyzed by multi photon confocal microscopy.
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PMAMPs, particularly PG1, can efﬁciently kill S. mutans apparently
through bacterial membrane disruption.
Themechanisms of action of PG1 have been explored suggesting
bacterial killing by permeabilizing their membranes via pore for-
mation [12]. Indeed, we observed that propidium iodide (PI), a cell-
impermeant molecule that only enters cells with damaged mem-
branes, rapidly gain intracellular access following PG1 exposure,
while SEM images of PG1 treated bacteria provide further evidence
of membrane structure disruption. However, the membrane-destabilizing mechanisms needs further elucidation, which may
involve complex surface charge alterations, penetration through
lipid bilayer of the membrane and PG1 interactions with negatively
charged molecules such as teichoic and lipoteichoic acid [52].
Further studies using ellipsometry, electrochemistry, and neutron
reﬂectometry combined with atomic force microscopy or NMR
shall elucidate both the molecular targets and structural changes
associated with membrane disruption [53e56]. In addition, the
observed selectivity between microbial and mammalian cells is
based on the amphipathic nature of antimicrobial peptides (AMPs),
Fig. 5. Bioﬁlm disruption by synthetic PG1 alone or in combination with EPS-degrading enzymes. (A) EPS-degrading enzymes digesting bioﬁlm matrix. Representative time-
lapsed images of EPS degradation in S. mutans bioﬁlm treated with combination of dextranase and mutanase. Bacterial cells were stained with SYTO 9 (in green) and EPS were
labeled with Alexa Fluor 647 (in red). The white arrows show ‘opening’ of spaces between the bacterial cell clusters and ‘uncovering’ cells following enzymatic degradation of EPS.
(B) Time-lapse quantiﬁcation of EPS degradation within intact bioﬁlms using COMSTAT. (C) The viability of S. mutans bioﬁlm treated with synthetic PG1 and EPS-degrading enzymes
(Dex/Mut) either alone or in combination by ImageJ. (D) Antibioﬁlm activity of synthetic PG1 or chlorhexidine was enhanced by EPS-degrading enzymes (Dex/Mut). Asterisks
indicate that the values for different experimental groups are signiﬁcantly different from each other (P < 0.05).
Fig. 6. Uptake of GFP fusion proteins by human periodontal and gingival cells and relative efﬁciency of GFP fused tags penetrating into human cell lines. (A) Human
periodontal ligament stem cells (HPDLS). (B) Maxilla mesenchymal stem cells (MMS). (C) Human head and neck squamous cell carcinoma cells (SCC). (D) Gingiva-derived
mesenchymal stromal cells (GMSC). (E) Adult gingival keratinocytes (AGK). (F) Mouse Osteoblast cell (OBC) with confocal microscopy. Human cell lines were cultured as
described in the methods section and incubated with GFP or GFP fusion proteins at indicated concentration. Scale bar represent 10 mm. All images studies have been analyzed in
triplicate. (G) Gingiva-derived mesenchymal stromal cells (GMSC). (H) Adult gingival keratinocytes (AGK). The GFP intensity were determined using ImageJ. Results are shown as
normalized GFP intensity of each GFP fusion protein in cell lines. One-way ANOVA showed signiﬁcant differences between groups (P < 0.0001) and t-test showed signiﬁcant
differences between two groups (*P < 0.05, **P < 0.01, ***P < 0.001).
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neutrally charged phosphatidylcholine on the outer cell surface and
negatively charged phosphatidylglycerol in the inner cytoplasmic
surface. In contrast, outer surface of bacteria contain negatively
charged lipids phosphatidylserine and phosphatidylglycerol as well
as lipopolysaccharides [16,52]. In Gram-positive bacteria (lipo)tei-
choic acids also contribute towards the net negative surface charge
hence making bacterial cells more anionic than mammalian cells
[16,52].
Protegrin has been tested in clinical studies to treat oral
mucositis in patients receiving chemotherapy in phase II, III clinical
studies and lack of toxicity against normal oral cells has been well
documented [57,58]. The range of concentrations used in this study
(<10 mg/ml) is several-fold less than that used in previous clinical
trials and toxicity studies. Furthermore, all human cell lines tested
remain morphologically intact after treatment with different GFP-
fused peptides as clearly observed in the confocal images, sug-
gesting lack of deleterious cellular effects at the tested concentra-
tions. Plant cells are routinely consumed and therefore impurities
in plant cell extracts have no negative impact [59] but this approach
signiﬁcantly reduces the cost by elimination of the expensive pu-
riﬁcation processes. Plant-made PG1 is highly bioactive with
similar efﬁcacy as the synthetic peptide (which cost ~$650,000/
gram [14]), demonstrating low cost potential of PMAMPs for bio-
ﬁlm inhibition. Currently there are no reports of successful pro-
duction of functional protegrin or retrocyclin in any biological
system. They are either chemically synthesized and refolded or
expressed as linear or fusion proteins, puriﬁed and refolded in vitro.
Ability to make fully functional PMAMPs facilitates their use in
topical oral formulations or in chewing gums, thereby eliminating
the puriﬁcation process and reducing cost.
Although AMPs have demonstrated great potential as antimi-
crobial agents, there are considerable challenges for their clinical
application, including stability of the peptides and their suscepti-
bility to proteolytic degradation. Previous studies have shown that
cyclization of linear peptides enhances stability to proteases [60],
while PG1 has been also shown to inhibit viral proteases [61].
Furthermore, we found that the presence of saliva (which contains
both mammalian and bacterial-derived proteolytic enzymes) did
not affect the antibacterial effects of PMAMPs (data not shown),
suggesting that the peptides were not degraded and the bioactivity
unaffected by the salivary proteases.
The main objective here is to develop a proof of concept that we
could use PMAMPs to impair bioﬁlm formation mediated by
S. mutans using topical treatment akin to clinical situation.
Currently, chlorhexidine (CHX) is the most effective antimicrobial
agent for topical use despite its adverse effects [6,10,11]. We
observed that PG1 was as potent as CHX, causing substantial
impairment of bioﬁlm formation with a single topical treatment of
a tooth-surrogate surface. Similar to CHX, PG1 is highly cationic
which could promote effective binding onto saliva-coated apatitic
surfaces, and thereby perform antibacterial activity in situ. Several
chemically synthesized antimicrobial peptides (AMPs) have been
tested against oral bacteria [12], including peptides with enhanced
speciﬁcity to S. mutans [13]. However, their antibioﬁlm efﬁcacy has
been mostly determined using continuous, prolonged exposure to
AMPs (several hours) rather than topical exposure and without
growing bioﬁlms under cariogenic conditions. Furthermore, syn-
thetic AMPs aremostly linear and expensive to producewhile being
less stable (vs. cyclic/hairpin), which provide barriers for product
development and storage [20e25]. In this study, we show that
PMAMPs with complex secondary structure (PG1) is an effective
inhibitor of bioﬁlm initiation. However, similar to CHX [47,62,63],
PMAMPs alone was less effective against developed S. mutans
bioﬁlms, which remains one of the major therapeutic challenges.Cariogenic bioﬁlms are characterized by bacteria forming clus-
ter (microcolonies) that are embedded in EPS matrix, making bio-
ﬁlm treatment and removal extremely difﬁcult [9,28,51,62]. This
ultimately promotes microbial adhesion and creates a highly
cohesive bioﬁlm that shelters resident organisms from antimicro-
bials while ensuring ﬁrm attachment on tooth surfaces [27e29].
Thus, EPS synthesis makes S. mutans a formidable opponent to oral
health. Here, we developed a novel synergistic concept of PMAMPs
and EPS matrix-degrading enzymes combination to disrupt pre-
formed bioﬁlms and kill embedded S. mutans cells. The EPS from
S. mutans are comprised primarily of insoluble (with high content
of a1,3 linked glucose) and soluble (mostly a1,6 linked glucose)
glucans [9]. Glucanohydrolases, dextranase (a1,6 glucanase) or
mutanase (a1,3 glucanase), have been explored to disrupt bioﬁlm
and prevent dental caries. However, topical applications of en-
zymes alone have generated moderate anti-bioﬁlm/anti-caries ef-
fects clinically, in part due to lack of antibacterial actions [34,64].
Results presented here show that dextranase and mutanase can
effectively digest the EPS covering and surrounding the bacterial
clusters, signiﬁcantly enhancing S. mutans killing by PMAMPs (~10-
fold increase). The glucanohydrolases alone had minimal effects
against bacterial viability supporting previous observations [34,64].
Conversely, PMAMPs exhibit no matrix degrading activity. We infer
that matrix structure degradation, especially the a1,3 and a1,6-
linked glucan backbone and the branch points 3,4- and 3,6-linked
glucose that are optimally digested with mutanase and dextranase
[43], facilitated PMAMPs access and killing of the exposed bacterial
clusters. However, further studies using time-lapse super-resolu-
tion 3D microscopy are required to determine the dynamics of
matrix degradation and PMAMPs penetration across the bioﬁlm
structure. Because PMAMPs fused with GFP is retaining potent
antimicrobial activity, it should facilitate their fusion with EPS
digesting enzymes in plant cells for their synergistic activities in
degrading the bioﬁlm matrix and killing embedded bacteria. This
topical antibioﬁlm approach based on plant-derived PDs could
drastically enhance disruption of virulent bioﬁlms by targeting
both the scaffold and bacterial viability, and advance to the clinic as
pioneered by Guy's plant monoclonal antibody for human immu-
notherapy [4].
Retention of high level antimicrobial activity by protegrin along
with GFP fusion opens the door for a number of clinical applications
to enhance oral health, beyond disruption of bioﬁlms. Several
challenges associated with the high cost and invasive surgical de-
livery of protein drugs in oral health can be addressed. In addition
to bioﬁlm disruption, enhancing wound healing in the gum tissues
is an important clinical need. We recently reported that both pro-
tegrin and retrocyclin can enter human mast cells and induce
degranulation, an important step in the wound healing process
[14]. Therefore, antimicrobial peptides protegrin and retrocyclin
could play an important role in killing bacteria in bioﬁlms and
initiate wound healing through degranulation of mast cells. In
addition, it is important to effectively deliver growth hormones or
other bioactive proteins to enhance cell adhesion, stimulate
osteogenesis, and differentiation of osteoblasts or endothelial cells.
Delivery efﬁcacy of GFP fused with each tag, independently, was
investigated. CTB is used as an ideal transmucosal carrier for oral
drug delivery because it enters all human cell types via GM1 re-
ceptors. Protein transduction domain (PTD) are small cationic
peptides that function as macromolecular transporters by receptor
independent, ﬂuid-phase macropinocytosis (a special type of
endocytosis) [59]. Therefore, we used both CTB and PTD fusion tags
as positive controls to evaluate the efﬁciency of antimicrobial
peptides penetrating human periodontal and gingival cells. GFP-
PG1 is the most efﬁcient tag in entering periodontal or gingival
human cells because GFP signal could be detected even at 40e48
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Indeed, protegrin is more efﬁcient in delivering fusion proteins to
human cell lines than any other cell penetrating peptide tested so
far. Although there were some variations in intracellular localiza-
tion, GFP-PG1 effectively entered HPDLSC, SCC-1, GMSC, AGK,
MMSC and OBC. In contrast GFP-RC101 entered SCC-1, GMSC, AGK
and OBC but its localization in HPDLSC and MMSC cells were poor
or undetectable. Therefore, this study has identiﬁed a novel role for
protegrin in delivering drugs to osteoblasts, periodontal ligament
cells, gingival epithelial cells or ﬁbroblasts. It is feasible to release
protein drugs synthesized in plant cells by mechanical grinding,
and protein drugs bioencapsulated in lyophilized plant cells
embedded in chewing gums could be an ideal mode of drug de-
livery for their slow and sustained release for longer duration. This
provides an alternative to current oral rinse formulations-short
duration of contact of antimicrobials on the gum/dental surface.
However, further in vivo and clinical studies are required to eval-
uate the anti-bioﬁlm/anti-caries efﬁcacy as well as targeted, sus-
tained drug-delivery in the oral cavity. Comprehensive in vivo
studies are underway to demonstrate that PMAMPs can be deliv-
ered to gum tissue without cytotoxicity and control bioﬁlm for-
mation/dental caries using appropriate human intra-oral models.
Beyond topical application, protein drugs fused with protegrin
expressed in plant cells has the potential to be orally delivered to
gum tissues in a non-invasive manner and increase patient
compliance. Protein drugs bioencapsulated in plants can be stored
for many years at room temperature without losing their efﬁcacy
[3,65]. The high cost of current protein drugs is due to their pro-
duction in prohibitively expensive fermenters, puriﬁcation, cold
transportation/storage, short shelf life and sterile deliverymethods.
All these challenges could be eliminated using this novel drug de-
livery concept to prevent bioﬁlm-related infections and enhance
oral health. Recent FDA approval of plant cells for production of
protein drugs [1] augurs well for clinical advancement of this novel
concept.
Acknowledgements
This study was supported by Bill and Melinda Gates Foundation
(OPP1031406), NIH grants R01 HL107904, R01 HL109442 and R01
EY 024564 to Henry Daniell, R01 DE18023 and R01 DE025220 to
Hyun Koo. We would like to thank the following for providing cell
cultures: Dr. Dana T. Graves (osteoblasts, gingival keratinocytes), Dr.
Ahn Lee (gingival mesenchymal, HPLSC, SSC-1), Dr. Sunday Akin-
toye's (MMS), Dr. Francis Mante (osteoblasts) and Dr. Songtao Shi
(periodontal ligament stem cells).
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.biomaterials.2016.07.042.
References
[1] G. Walsh, Biopharmaceutical benchmarks, Nat. Biotechnol. 32 (2014)
992e1000.
[2] K.C. Kwon, H. Daniell, Low-cost oral delivery of protein drugs bioencapsulated
in plant cells, Plant Biotechnol. J. 13 (2015) 1017e1022.
[3] H. Daniell, C.S. Lin, M. Yu, W.J. Chang, Chloroplast genomes: diversity, evo-
lution and applications in genetic engineering, Genome Biol. 17 (2016), http://
dx.doi.org/10.1186/s13059-016-1004-2.
[4] J.K. Ma, B.Y. Hikmat, K. Wycoff, N.D. Vine, D. Chargelegue, L. Yu, et al., Char-
acterization of a recombinant plant monoclonal secretory antibody and pre-
ventive immunotherapy in humans, Nat. Med. 4 (1998) 601e606.
[5] C. Arntzen, Plant-made pharmaceuticals: from ‘Edible Vaccines’ to Ebola
therapeutics, Plant Biotechnol. J. 13 (2015) 1013e1016.
[6] T.F. Flemmig, T. Beikler, Control of oral bioﬁlms, Periodontol. 2000 55 (2011)
9e15.[7] L. Hall-Stoodley, J.W. Costerton, P. Stoodley, Bacterial bioﬁlms: from the nat-
ural environment to infectious diseases, Nat. Rev. Microbiol. 2 (2004) 95e108.
[8] N.J. Kassebaum, E. Bernabe, M. Dahiya, B. Bhandari, C.J. Murray, W. Marcenes,
Global burden of untreated caries: a systematic review and metaregression,
J. Dent. Res. 94 (2015) 650e658.
[9] W.H. Bowen, H. Koo, Biology of Streptococcus mutans-derived glucosyl-
transferases: role in extracellular matrix formation of cariogenic bioﬁlms,
Caries Res. 45 (2011) 69e86.
[10] P.D. Marsh, A. Moter, D.A. Devine, Dental plaque bioﬁlms: communities,
conﬂict and control, Periodontol. 2000 55 (2011) 16e35.
[11] J. Autio-Gold, The role of chlorhexidine in caries prevention, Oper. Dent. 33
(2008) 710e716.
[12] B.R. da Silva, V.A. de Freitas, L.G. Nascimento-Neto, V.A. Carneiro, F.V. Arruda,
A.S. de Aguiar, et al., Antimicrobial peptide control of pathogenic microor-
ganisms of the oral cavity: a review of the literature, Peptides 36 (2012)
315e321.
[13] L. Guo, J.S. McLean, Y. Yang, R. Eckert, C.W. Kaplan, P. Kyme, et al., Precision-
guided antimicrobial peptide as a targeted modulator of human microbial
ecology, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 7569e7574.
[14] K. Gupta, A. Kotian, H. Subramanian, H. Daniell, H. Ali, Activation of human
mast cells by retrocyclin and protegrin highlight their immunomodulatory
and antimicrobial properties, Oncotarget 6 (2015) 28573e28587.
[15] R. Koczulla, G. von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, T. Gloe, et al., An
angiogenic role for the human peptide antibiotic LL-37/hCAP-18, J. Clin.
Invest. 111 (2003) 1665e1672.
[16] S. Lee, B. Li, S. Jin, H. Daniell, Expression and characterization of antimicrobial
peptides Retrocyclin-101 and Protegrin-1 in chloroplasts to control viral and
bacterial infections, Plant Biotechnol. J. 9 (2011) 100e115.
[17] G. DeGray, K. Rajasekaran, F. Smith, J. Sanford, H. Daniell, Expression of an
antimicrobial peptide via the chloroplast genome to control phytopathogenic
bacteria and fungi, Plant Physiol. 127 (2001) 852e862.
[18] D. Andersson, D. Hughes, J. Kubicek-Sutherland, Mechanisms and conse-
quences of bacterial resistance to antimicrobial peptides, Drug resist. Updat
26 (2016) 43e57.
[19] V. Nizet, Antimicrobial peptide resistance mechanisms of human bacterial
pathogens, Curr. Issues. Mol. Biol. 8 (2006) 11e26.
[20] W. Wang, A.M. Cole, T. Hong, A.J. Waring, R.I. Lehrer, Retrocyclin, an antire-
troviral theta-defensin, is a lectin, J. Immunol. 170 (2003) 4708e4716.
[21] J. Chen, T.J. Falla, H. Liu, M.A. Hurst, C.A. Fujii, D.A. Mosca, et al., Development
of protegrins for the treatment and prevention of oral mucositis: structure-
activity relationships of synthetic protegrin analogues, Biopolymers 55
(2000) 88e98.
[22] A.B. Sassi, K.E. Bunge, B.L. Hood, T.P. Conrads, A.M. Cole, P. Gupta, et al., Pre-
formulation and stability in biological ﬂuids of the retrocyclin RC-101, a po-
tential anti-HIV topical microbicide, AIDS Res. Ther. 8 (2011) 27.
[23] A.B. Sassi, M.R. Cost, A.L. Cole, A.M. Cole, D.L. Patton, P. Gupta, et al., Formu-
lation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal
microbicide product, Antimicrob. Agents Chemother. 55 (2011) 2282e2289.
[24] J.R. Lai, B.R. Huck, B. Weisblum, S.H. Gellman, Design of non-cysteine-
containing antimicrobial b-hairpins: structure-activity relationship studies
with linear protegrin-1 analogues, Biochemistry 41 (2002) 12835e12842.
[25] Z. Ma, D. Wei, P. Yan, X. Zhu, A. Shan, Z. Bi, Characterization of cell selectivity,
physiological stability and endotoxin neutralization capabilities of a-helix-
based peptide amphiphiles, Biomaterials 52 (2015) 517e530.
[26] J.T. Mika, G. Moiset, A.D. Cirac, L. Feliu, E. Bardají, M. Planas, et al., Structural
basis for the enhanced activity of cyclic antimicrobial peptides: the case of
BPC194, Biochim. Biophys. Acta. (BBA)-Biomembranes 1808 (2011)
2197e2205.
[27] H. Flemming, J. Wingender, The bioﬁlm matrix, Nat. Rev. Microbiol. 8 (2010)
623e633.
[28] H. Koo, M.L. Falsetta, M.I. Klein, The exopolysaccharide matrix: a virulence
determinant of cariogenic bioﬁlm, J. Dent. Res. 92 (2013) 1065e1073.
[29] B.W. Peterson, Y. He, Y. Ren, A. Zerdoum, M.R. Libera, P.K. Sharma, et al.,
Viscoelasticity of bioﬁlms and their recalcitrance to mechanical and chemical
challenges, FEMS Microbiol. Rev. 39 (2015) 234e245.
[30] W.H. Bowen, The effect of dextranase on caries activity in monkeys (macaca
irus), Caries Res. 6 (1972) 75e76.
[31] B. Guggenheim, B. Regolati, R. Schmid, H. Mühlemann, Effects of the topical
application of mutanase on rat caries, Caries Res. 14 (1980) 128e135.
[32] Y. Jiao, S. Wang, M. Lv, B. Jiao, W. Li, Y. Fang, et al., Characterization of a
marine-derived dextranase and its application to the prevention of dental
caries, J. Ind. Microbiol. Biotechnol. 41 (2014) 17e26.
[33] R. Otsuka, S. Imai, T. Murata, Y. Nomura, M. Okamoto, H. Tsumori, et al.,
Application of chimeric glucanase comprising mutanase and dextranase for
prevention of dental bioﬁlm formation, Microbiol. Immunol. 59 (2015) 28e36.
[34] P. Hull, Chemical inhibition of plaque, J. Clin. Periodontol. 7 (1980) 431e442.
[35] M. Balakrishnan, R.S. Simmonds, J.R. Tagg, Dental caries is a preventable in-
fectious disease, Aust. Dent. J. 45 (2000) 235e245.
[36] P. Agrawal, D. Verma, H. Daniell, Expression of Trichoderma reesei b-man-
nanase in tobacco chloroplasts and its utilization in lignocellulosic woody
biomass hydrolysis, PloS One 6 (2011) e29302.
[37] S. Jin, A. Kanagaraj, D. Verma, T. Lange, H. Daniell, Release of hormones from
conjugates: chloroplast expression of beta-glucosidase results in elevated
phytohormone levels associated with signiﬁcant increase in biomass and
protection from aphids or whiteﬂies conferred by sucrose esters, Plant
Y. Liu et al. / Biomaterials 105 (2016) 156e166166Physiol. 155 (2011) 222e235.
[38] K.C. Kwon, D. Verma, N.D. Singh, R. Herzog, H. Daniell, Oral delivery of human
biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in
plant cells, Adv. Drug Deliv. Rev. 65 (2013) 782e799.
[39] P.S. Lakshmi, D. Verma, X. Yang, B. Lloyd, H. Daniell, Low cost tuberculosis
vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation,
stability and functional evaluation in vitro, PLoS One 8 (2013) e54708.
[40] D. Ajdic, W.M. McShan, R.E. McLaughlin, G. Savic, J. Chang, M.B. Carson, et al.,
Genome sequence of Streptococcus mutans UA159, a cariogenic dental
pathogen, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14434e14439.
[41] S.E. Whitmore, R.J. Lamont, The pathogenic persona of community-associated
oral streptococci, Mol. Microbiol. 81 (2011) 305e314.
[42] I. Dige, M.K. Raarup, J.R. Nyengaard, M. Kilian, B. Nyvad, Actinomyces nae-
slundii in initial dental bioﬁlm formation, Microbiology 155 (2009)
2116e2126.
[43] M.F. Hayacibara, H. Koo, A.M.V. Smith, L.K. Kopec, K. Scott-Anne, J.A. Cury, et
al., The inﬂuence of mutanase and dextranase on the production and structure
of glucans synthesized by streptococcal glucosyltransferases, Carbohydr. Res.
339 (2004) 2127e2137.
[44] Y. Xiao, K.C. Kwon, B.E. Hoffman, A. Kamesh, N.T. Jones, R.W. Herzog, et al.,
Low cost delivery of proteins bioencapsulated in plant cells to human non-
immune or immune modulatory cells, Biomaterials 80 (2016) 68e79.
[45] A. Limaye, V. Koya, M. Samsam, H. Daniell, Receptor-mediated oral delivery of
a bioencapsulated green ﬂuorescent protein expressed in transgenic chloro-
plasts into the mouse circulatory system, FASEB J. 20 (2006) 959e961.
[46] H. Koo, P.L. Rosalen, J.A. Cury, Y.K. Park, W.H. Bowen, Effects of compounds
found in propolis on Streptococcus mutans growth and on glucosyltransferase
activity, Antimicrob. Agents Chemother. 46 (2002) 1302e1309.
[47] J. Xiao, M.I. Klein, M.L. Falsetta, B. Lu, C.M. Delahunty, J.R. Yates, et al., The
exopolysaccharide matrix modulates the interaction between 3D architecture
and virulence of a mixed-species oral bioﬁlm, PLoS Pathog. 8 (2012)
e1002623.
[48] H. Koo, J. Xiao, M.I. Klein, J.G. Jeon, Exopolysaccharides produced by Strep-
tococcus mutans glucosyltransferases modulate the establishment of micro-
colonies within multispecies bioﬁlms, J. Bacteriol. 192 (2010) 3024e3032.
[49] M.I. Klein, K.M. Scott-Anne, S. Gregoire, P.L. Rosalen, H. Koo, Molecular ap-
proaches for viable bacterial population and transcriptional analyses in a ro-
dent model of dental caries, Mol. oral Microb. 27 (2012) 350e361.
[50] T. Ohashi, S.D. Galiacy, G. Briscoe, H.P. Erickson, An experimental study of
GFP-based FRET, with application to intrinsically unstructured proteins, Pro-
tein Sci. 16 (2007) 1429e1438.
[51] A.F. Paes Leme, H. Koo, C.M. Bellato, G. Bedi, J.A. Cury, The role of sucrose in
cariogenic dental bioﬁlm formationenew insight, J. Dent. Res. 85 (2006)
878e887.
[52] K. Matsuzaki, Control of cell selectivity of antimicrobial peptides, Biochim.Biophys. Acta (BBA)-Biomembranes 1788 (2009) 1687e1692.
[53] A. Schmidtchen, L. Ringstad, G. Kasetty, H. Mizuno, M.W. Rutland,
M. Malmsten, Membrane selectivity by W-tagging of antimicrobial peptides,
Biochim. Biophys. Acta (BBA)-Biomembranes 1808 (2011) 1081e1091.
[54] L. Ringstad, E. Protopapa, B. Lindholm-Sethson, A. Schmidtchen, A. Nelson,
M. Malmsten, An electrochemical study into the interaction between
complement-derived peptides and DOPC mono-and bilayers, Langmuir 24
(2008) 208e216.
[55] A.J. García-Saez, S. Chiantia, J. Salgado, P. Schwille, Pore formation by a Bax-
derived peptide: effect on the line tension of the membrane probed by
AFM, Biophys. J. 93 (2007) 103e112.
[56] D.I. Fernandez, A.P. Le Brun, T.C. Whitwell, M. Sani, M. James, F. Separovic, The
antimicrobial peptide aurein 1.2 disrupts model membranes via the carpet
mechanism, Phy. Chem. Chem. Phy. 14 (2012) 15739e15751.
[57] F.J. Giles, C.B. Miller, D.D. Hurd, J.R. Wingard, T.R. Fleming, S.T. Sonis, et al.,
A phase III, randomized, double-blind, placebo-controlled, multinational trial
of iseganan for the prevention of oral mucositis in patients receiving stoma-
totoxic chemotherapy (PROMPT-CT trial), Leuk. Lymphoma 44 (2003)
1165e1172.
[58] A. Trotti, A. Garden, P. Warde, P. Symonds, C. Langer, R. Redman, et al.,
A multinational, randomized phase III trial of iseganan HCl oral solution for
reducing the severity of oral mucositis in patients receiving radiotherapy for
head-and-neck malignancy, Int. J. Radiat. Oncol. Biol. Phys. 58 (2004)
674e681.
[59] K.C. Kwon, H. Daniell, Oral delivery of protein drugs bioencapsulated in plant
cells, Mol. Ther. 5 (2016), http://dx.doi.org/10.1038/mt.2016.115.
[60] A. Rozek, J.S. Powers, C.L. Friedrich, R.E. Hancock, Structure-based design of an
indolicidin peptide analogue with increased protease stability, Biochemistry
42 (2003) 14130e14138.
[61] H.A. Rothan, A.Y. Abdulrahman, P.G. Sasikumer, S. Othman, N.A. Rahman,
R. Yusof, Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral
replication in MK2 cells, J. Biomed. Biotechnol. (2012) 251482.
[62] C.K. Hope, M. Wilson, Analysis of the effects of chlorhexidine on oral bioﬁlm
vitality and structure based on viability proﬁling and an indicator of mem-
brane integrity, Antimicrob. Agents Chemother. 48 (2004) 1461e1468.
[63] D.A. Van Strydonck, D.E. Slot, U. Van der Velden, F. Van der Weijden, Effect of a
chlorhexidine mouthrinse on plaque, gingival inﬂammation and staining in
gingivitis patients: a systematic review, J. Clin. Periodontol. 39 (2012)
1042e1055.
[64] M. Pleszczynska, A. Wiater, M. Janczarek, J. Szczodrak, (1/ 3)-a-d-Glucan
hydrolases in dental bioﬁlm prevention and control: a review, Int. J. Biol.
Macromol. 79 (2015) 761e778.
[65] J. Su, L. Zhu, A. Sherman, X. Wang, S. Lin, A. Kamesh, et al., Low cost industrial
production of coagulation factor IX bioencapsulated in lettuce cells for oral
tolerance induction in hemophilia B, Biomaterials 70 (2015) 84e93.
